Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results